基本信息
浏览量:3
职业迁徙
个人简介
My Research
KEYWORDS
chromatin modifications in development and oncogenesis, cancer, genome integrity, pharmacology, stem cell biology
SUMMARY
The research interests of our laboratory center on chromatin modifications and its impact on regulation of gene expression and nuclear structure, particularly as it relates changes associated with malignant transformation. Clearly, the interplay between activation and repression of transcription that imposes normal transcriptional control becomes disrupted in cancer. Besides their roles in promoter-specific transcriptional regulation, histone modifiers also play a role in the establishment of large chromosomal domains, and therefore function in maintenance of chromosomal integrity. We and others have shown that deregulation of histone modifying complexes, including Histone Deacetylases (HDACs)-containing complexes, participate to the oncogenic transformation in numerous human cancers. Several studies suggested that blocking the enzymatic activity of HDAC complexes (e.g., using histone deacetylase inhibitors) could prevent tumorigenesis and selectively induce cell death in transformed cells. While HDACs are integral components of several gene regulatory complexes, HDAC inhibitors developed to date exhibit little or no specificity towards individual HDAC-containing complex. Thus, the identification of pathways involved in the modulation of the activities of specific HDAC complexes is a priority in cancer therapy. Knowledge of these control mechanisms in both normal physiology and malignancy is essential for the better understanding of the malignant process that will allow development of novel therapeutic and diagnostic approaches to human disease.
We have recently developed valuable biological tools to study the prominent HDAC-containing complex in mammalian cells, the mSin3-HDAC complex. The mSin3 complex was the first chromatin modifying complex shown to be deregulated in human cancers. However, the molecular basis for the malignant phenotype in those tumors remain unclear, impairing the development of efficient targeted therapies. Using genetic recombination, we generated mouse strains that can be spatially and temporally genetically inactivated for different components of the mSin3-HDAC complex. Those unique reagents will enable the precise delineation of the in vivo consequences of deregulation or inactivation of the complex on mammalian development and oncogenesis, and enable the development of rational targeted therapies.
KEYWORDS
chromatin modifications in development and oncogenesis, cancer, genome integrity, pharmacology, stem cell biology
SUMMARY
The research interests of our laboratory center on chromatin modifications and its impact on regulation of gene expression and nuclear structure, particularly as it relates changes associated with malignant transformation. Clearly, the interplay between activation and repression of transcription that imposes normal transcriptional control becomes disrupted in cancer. Besides their roles in promoter-specific transcriptional regulation, histone modifiers also play a role in the establishment of large chromosomal domains, and therefore function in maintenance of chromosomal integrity. We and others have shown that deregulation of histone modifying complexes, including Histone Deacetylases (HDACs)-containing complexes, participate to the oncogenic transformation in numerous human cancers. Several studies suggested that blocking the enzymatic activity of HDAC complexes (e.g., using histone deacetylase inhibitors) could prevent tumorigenesis and selectively induce cell death in transformed cells. While HDACs are integral components of several gene regulatory complexes, HDAC inhibitors developed to date exhibit little or no specificity towards individual HDAC-containing complex. Thus, the identification of pathways involved in the modulation of the activities of specific HDAC complexes is a priority in cancer therapy. Knowledge of these control mechanisms in both normal physiology and malignancy is essential for the better understanding of the malignant process that will allow development of novel therapeutic and diagnostic approaches to human disease.
We have recently developed valuable biological tools to study the prominent HDAC-containing complex in mammalian cells, the mSin3-HDAC complex. The mSin3 complex was the first chromatin modifying complex shown to be deregulated in human cancers. However, the molecular basis for the malignant phenotype in those tumors remain unclear, impairing the development of efficient targeted therapies. Using genetic recombination, we generated mouse strains that can be spatially and temporally genetically inactivated for different components of the mSin3-HDAC complex. Those unique reagents will enable the precise delineation of the in vivo consequences of deregulation or inactivation of the complex on mammalian development and oncogenesis, and enable the development of rational targeted therapies.
研究兴趣
论文共 82 篇作者统计合作学者相似作者
按年份排序按引用量排序主题筛选期刊级别筛选合作者筛选合作机构筛选
时间
引用量
主题
期刊级别
合作者
合作机构
Epigenetics & Chromatinno. 1 (2024): 2-2
crossref(2023)
crossref(2023)
Kathryn B. Grandinetti,Petar Jelinic, Teresa DiMauro, Jessica Pellegrino, Rubén Fernández Rodríguez, Patricia M. Finnerty,Rachel Ruoff,Nabeel Bardeesy,Susan K. Logan,Gregory David
crossref(2023)
biorxiv(2023)
crossref(2023)
加载更多
作者统计
合作学者
合作机构
D-Core
- 合作者
- 学生
- 导师
数据免责声明
页面数据均来自互联网公开来源、合作出版商和通过AI技术自动分析结果,我们不对页面数据的有效性、准确性、正确性、可靠性、完整性和及时性做出任何承诺和保证。若有疑问,可以通过电子邮件方式联系我们:report@aminer.cn